. Global differences in lung function by region (PURE): an international, community-based prospective study.
Introduction
The global rise in disease burden from chronic respiratory diseases 1 means that more information is needed about global lung health, particularly factors that adversely affect lung function. 2 Differences in lung function between ethnic groups have previously been investigated, but generally within one country or region. 3 The most widely reported comparisons of lung function (forced expiratory volume in 1 s [FEV 1 ] and forced vital capacity [FVC] ) are between white people and African Americans (decrease of 10-15% 4,5 ) and between white people and individuals of Asian origin (decrease of 6-12% 6,7 ). Few data are available for other ethnic groups and populations in different geographical regions with vastly different socioeconomic and environmental exposures that could affect lung function. 8
Our aim was to document the risk factors for chronic respiratory disease burden in adults globally. We deliberately oversampled countries of low to middle income, where the disease burden is high 9 and expected to rise further; little information about lung function and lung health is available for these regions. We postulated that, after adjustment for height, age, and sex, substantial global differences in lung function would be recorded, which would be a result of the complex interactions between genes and environment for each region. These differences could contribute to the baseline population risk for chronic respiratory disease and the global disparity in disease burden.
Methods

Study design and participants
In the international, community-based prospective Population Rural Urban Epidemiology (PURE) study, we enrolled individuals aged 34-80 years from 628 urban and rural communities in 17 countries across five continents. Enrolment occurred between Jan 1, 2005, and Dec 31, 2009, except in Karnataka, India, where it began on Jan 1, 2003.
Details of the enumeration and recruitment methods are provided in the appendix and have been reported elsewhere. 10 We used a multistage, convenience-sampled survey; countries and communities were chosen purposively in the first and second stages, and households or individuals were selected by random sampling in the third stage. We selected countries in different phases of epidemiological transition and where long-term followup was possible. The primary sample unit was the community. We selected a diverse sample of communities in each country purposefully, conveniently, or randomly (appendix), with stratification by urban or rural location.
https://repository.uwc.ac.za/
In each community, we used a sampling framework to recruit a representative sample of households. In all countries of low to middle income, door-to-door visits were done by trained local staff. In high-income countries, information about the study was initially sent to selected households by post. Study staff subsequently made telephone calls to the selected households, inviting eligible representatives to a central clinic. For both approaches, at least three attempts to contact an individual in each household were made. Households were eligible if at least one member was aged 35-70 years and intended to stay at the address for a further 4 years.
All eligible individuals in the selected households who provided written informed consent were enrolled. When an eligible household or individual refused to participate, demographic information and data about tobacco use, education, and history of cardiovascular disease were recorded in a non-responder form.
The study was coordinated by the Population Health Research Institute (Hamilton, ON, Canada). The protocol was approved by the Hamilton Health Sciences Research Ethics Board and by the local ethics committee at each site.
Procedures
At a second household visit (countries of low and middle income) or during participants' visit to a central clinic (high-income countries), local staff recorded information about demography, medical diagnoses, ethnic origin, tobacco use history, and respiratory symptoms with interview-based questionnaires. 11-14 Questionnaires were translated into the local language with a standardised protocol (appendix). During the second household visit in countries of low and middle income, an appointment was scheduled for physical measurements (including spirometry) and blood and urine tests.
During this appointment, or at the visit to the central clinic in high-income countries, weight was measured on calibrated scales with as little clothing as possible and without shoes. Height was measured with a Frankfort plane against a flat wall, with heels together.
A portable device (MicroGP, MicroMedical, Chatham, IL, USA), chosen for its affordability and ease of use, was used for spirometry measurements, but did not generate flow-volume loops (FVLs). Each participant attempted up to six prebronchodilator forced expiratory manoeuvres while standing and wearing a nose clip. Measurements of maximum effort and forced exhalation for at least 6 s were taken. The three highest measurements of FEV 1 , FVC, and peak expiratory flow (PEF) were recorded. Spirometer calibration with a 3 L syringe was done monthly and when thought necessary by local staff (eg, before use in extreme temperatures).
Data quality was maintained in three ways. First, key staff from each centre attended regional training sessions, in which standardised protocols and materials were used. These key staff in turn trained local staff. Local staff were tested on mock participants and certified. Retraining and certification occurred every 18 months. Second, prospective validation was done in 11 countries (Brazil, Canada, China, Colombia, India, Iran, Malaysia, South Africa, Sweden, Turkey, and United Arab Emirates) where study centres had access to pulmonary function https://repository.uwc.ac.za/ laboratories. The first 30 participants who attended follow-up visits at the study centre with the highest number of participants in each country were included in prospective validation. Con-current measurements with PURE methods (as used in the field) and in a pulmonary function laboratory (appendix) were obtained for these participants. In South Africa, spirograms were produced at baseline, meaning that FVL measurements were available.
Third, data were entered electronically into a customised database programmed with range and consistency checks and transmitted to the coordinating centre. Cases with missing values, transcription errors, or implausible data that could not be reconciled were removed.
For analyses, we selected participants with at least two measurements of FEV 1 and FVC with maximum effort, without cough and within 200 mL variability for analysis. Individuals for whom the highest FEV 1 divided by the highest FVC was 0·95 or higher, or less than 0·66, or for whom the highest PEF divided by the highest FEV 1 was less than 1·5 were deemed to have made less than maximum effort and were excluded. We derived these cutoffs from centres with high-quality data for acceptable maximum expiratory effort and forced expiratory time. We removed outliers that had an effect (with Cook's D statistic). Additionally, we excluded participants younger than 34 years and older than 80 years, and those shorter than 130 cm or taller than 190 cm from analyses because of small numbers. Further exclusion criteria were tobacco use of more than 5 pack-years, chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, cancer, pregnancy, regular use of respiratory medications, symptoms of breathlessness with usual activity in the previous 6 months, wheeze, haemoptysis, morning cough, chest tightness, or daily productive cough for 3 months a year for at least 2 years. We examined model fit by two methods (appendix). First, we used internal validation, deriving the model from a randomly selected subpopulation (80%) and examining model fit on the remaining 20%. This method showed no significant difference between the observed and predicted values. Second, we used face validity by showing that the standardised lung function values (ie, percentage of predicted) in participants with COPD, asthma, tuberculosis, and heart disease showed the expected pattern of impairment in these disorders.
We deemed a p value of less than 0·001 to be significant. All analyses were done with Statistica (version 10).
Role of the funding source
The sponsors of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. MD and SY had full access to all the data in the study and had final responsibility for the decision to submit for publication.
https://repository.uwc.ac.za/ Results 153 996 individuals were enrolled from the 628 communities ( figure 1 ). The countries with the highest numbers of participants were China and India (table 1). The proportion of unacceptable data was highest for South America and lowest for North America or Europe (table 2) . The large amount of unacceptable data was not associated with low unadjusted lung function measurements (table 2) . Healthy individuals excluded because of unacceptable data had similar baseline characteristics to individuals included in the study, confirming that the analysed population was a representative sample (appendix). Other common reasons for exclusion were respiratory symptoms, specified disorders (eg, asthma, HIV, or malaria) or pregnancy, and tobacco smoking (table 2) .
8 501 individuals participated in prospective validation. The difference between FEV 1 measurements in the field and the laboratory was small (≤200 mL) for all regions (appendix), suggesting that field measurements of FEV 1 were valid. Differences in FVC measurements of greater than 200 mL were recorded in South America, the Middle East, and east Asia (appendix To assess for potential confounders of this regional difference, we added other covariates, such as education level, urban versus rural location, and weight to the base model (tables 4, 5). Although these variables significantly contributed to lung function, they had little effect on regional lung function differences and therefore were not confounders (tables 4, 5). Furthermore, the fit of the model did not improve (no increase in pseudo-R²; tables 4, 5).
The ratio between FEV 1 and FVC was inversely correlated to height and age, but had no association with sex ( figure 4 ). The ratio differed by region for any height, age, and sex ( figure  4 ).
Discussion
To our knowledge, we have provided the first large-scale assessment of global variation in lung function in asymptomatic non-smokers in different regions of the world (panel However, such changing characteristics have not been shown in European populations. 24, 25 We speculated that the higher socioeconomic status and living standards of populations of European descent are similar and stable across time and place, allowing maximum lung function to be attained and leaving little room for further improvement or variation. In support of this hypothesis, we recorded that the usual predictors (height, age, and sex) explained a higher proportion of lung function variability in North America or Europe and the Middle East, where mainly high-income and urban-dominated countries were included, than elsewhere. Regions of low or middle income are more contextually diverse than those of high income, with varying conditions that can adversely affect lung function, leading to a greater unexplained variance in lung function.
Reported adverse conditions include early life exposures to outdoor 26 and indoor air pollution, 27 second-hand cigarette smoke, 28 respiratory infections, 29 nutritional factors, 30 overcrowding, 31 and low birthweight. 32 Failure to adjust for socioeconomic status (and the associated risk factors) has been proposed to confound the relation between ethnic origin or regions and low lung function. 3,8 However, adjustment for weight (for body dimension), urban versus rural location (physical environment), and education level (socioeconomic status) had little effect on the lung function gradient across regions in our study. This finding suggests that the situation is far more complex than previously thought, that the regional lung function difference is a result https://repository.uwc.ac.za/ of wide-ranging effects of known and unknown factors, and that the interaction between genes and the environment cannot be fully adjusted for within one model. Several aspects and limitations of our study need further discussion. First, we took a sociogeographic approach to the comparison of lung function, because it will set the framework for future analyses of the contextual mechanisms contributing to lung health inequalities across regions. However, this cross-sectional analysis cannot delineate the effects of genes versus contextual factors on lung function. As lung function in regions undergoing socioenvironmental changes driven by economic growth is tracked, the contextual and genetic effect can be better defined.
Second, our statistical approach was based on biologically plausible principles combined with robust regression modelling that can handle data that do not meet linear model assumptions (non-linear associations between predictors and lung function, and non-constant variability). It also allows for the complex interactions between the explanatory variables of lung function. This scaling of differences in lung function relative to North America or Europe is similar to an approach endorsed by the American Thoracic Society and the European Respiratory Society. 25
Third, the scale of our study, most of which was done in resource-challenged and remote areas, meant that use of advanced, costly spirometers that can provide FVL was https://repository.uwc.ac.za/ impractical. Therefore, we were unable to retrospectively verify data from individuals and instead used other criteria to validate our data epidemiologically, such as selection of recordings that meet criteria of the American Thoracic Society or European Respiratory Society for maximum effort (repeatability, without cough, and >6 s), comparisons of reported and predicted values for small differences (internal validity), establishment of the expected changes in spirometry values for individuals with various medical disorders (face validity), and investigation of agreement between field and pulmonary laboratory measurements in 501 participants from 11 countries (external validity). Furthermore, our findings are in keeping with other studies that have shown that individuals from North America and Europe have the highest lung function but lowest ratio of FEV 1 to FVC compared with some other ethnic or geographical groups. 4,25 Similarly, the key questionnaires (demographics and tobacco-use history) were taken from large international epidemiological studies 13,14 that have been translated and applied to regions or countries that are similar to those included in our study. Information about symptoms was internally validated by comparison of lung function differences between participants with and without symptoms. Moreover, all centres and operators were trained in the same way on the same equipment and questionnaires. Together with the large sample size and numbers of included centres in each region, the validation will mean measurement errors (if present) are random and therefore would tend to underestimate the true differences between regions. Collectively, these considerations give us confidence about the validity of the group data generated by our study.
Finally, postbronchodilator measurements were not feasible at baseline data collection, in view of the scale of our study, but are recommended by international guidelines for the diagnosis of airway diseases. 36 However, we used the same inclusion and exclusion criteria and prebronchodilator values as in other studies that examined lung function differences between ethnic groups, meaning that our conclusions can be compared with reported data. 4,6,25 Although differences between the prebronchodilator and postbronchodilator values have since been shown to be small in healthy European populations, 37 no similar information about populations outside of this region is available. These differences will be investigated in a subgroup of PURE in the next phase of data collection to address the issue of subclinical diseases in regions of low and middle income.
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